

Clinical Trial Protocol

Iranian Registry of Clinical Trials

31 Jul 2026

A single-arm multicenter clinical trial to evaluate the safety and efficacy of Remdesivir in COVID-19 patients with progressive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Protocol summary

Study aim

The aim of the study is to evaluate the safety and efficacy of Remdesivir in the treatment of COVID-19

Design

This study is a single-arm, uncontrolled, open-label clinical trial to evaluate the safety and efficacy of Remdesivir in COVID-19 patients.

Settings and conduct

This multicenter, single-arm, open-label clinical trial will be carried out from March 20, 2020, in different medical universities of Iran. Each recruitment center consecutively enrolls between 5 and 10 eligible patients who meet the eligibility criteria and sign the informed consent by themselves or their guardians (in case of decreased level of consciousness or cognitive impairment). Eligible patients are followed for 14 days (from the beginning of the intervention). Each hospital will report its findings to the DSMB after the enrolling of the three patients. They may enroll subsequent patients, after obtaining authorization from DSMB. Primary outcomes and serious adverse events (SAEs) will be received daily. Secondary outcomes and paraclinical and radiologic details of patients will be obtained through hospital records (due to the workload of centers).

Participants/Inclusion and exclusion criteria

Inclusion criteria: All confirmed COVID-19 patients who are still progressing despite receiving standard treatment. Exclusion criteria: Different treatment with national protocol, under mechanical ventilation and evidence of multiple organ failure.

Intervention groups

Patients in the intervention group receive remdesivir (200 mg on the first day followed by 100 mg per day) in addition to the standard treatment

Main outcome variables

TTCl: time (day) to clinical improvement (2 score improvement of six categorical scores ranging from

death to complete recovery) and TTCR: time (hr) to the normalization of fever, respiration, cough, and blood oxygen level is considered as the primary outcomes of this study.

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20171122037571N2**

Registration date: **2020-04-12, 1399/01/24**

Registration timing: **registered_while_recruiting**

Last update: **2020-04-12, 1399/01/24**

Update count: **0**

Registration date

2020-04-12, 1399/01/24

Registrant information

Name

Hamed Hosseini

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 21 8670 5503

Email address

hmdhosseini@gmail.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2020-03-20, 1399/01/01

Expected recruitment end date

2020-05-19, 1399/02/30

Actual recruitment start date

empty

Actual recruitment end date
empty

Trial completion date
empty

Scientific title
A single-arm multicenter clinical trial to evaluate the safety and efficacy of Remdesivir in COVID-19 patients with progressive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Public title
Remdesivir in treatment of COVID-19

Purpose
Treatment

Inclusion/Exclusion criteria
Inclusion criteria:
Ability to fully understand, willingness to participate, and signing the informed consent form (in case of decreased level of consciousness or/ and cognitive impairment, informed consent is obtained from their legal representative) Ages over 18 years Patients with a definitive diagnosis of SARS-CoV-2 virus based on PCR with specific pulmonary involvement in radiography who have progressive hospital course (SpO2 <85% or RR > 30) despite receiving standard of care treatment protocols within 72 hours
Exclusion criteria:
Participants in any other clinical trial for COVID-19 Concomitant treatment with other antiviral drugs other than those recommended in the national protocol Patients undergoing mechanical ventilation at the time of baseline Evidence of multiorgan failure in the patient's clinical record based on the physician's diagnosis Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) above 5 times the upper limit of normal (ULN) Creatinine clearance less than 50 ml/min The presence of any concurrent major diseases including malignancy, advanced heart failure, cirrhosis, chronic kidney disease, stroke, Alzheimer's, chronic progressive neurological diseases, etc. Pregnant and lactating women Possibility of being transferred to another hospital with no access to the study drug (for any reason)

Age
From **18 years** old

Gender
Both

Phase
2-3

Groups that have been masked
No information

Sample size
Target sample size: **120**

Randomization (investigator's opinion)
N/A

Randomization description

Blinding (investigator's opinion)
Not blinded

Blinding description

Placebo
Not used

Assignment
Single

Other design features
Medicine used in study was provided by International donation as Compassionate use under the supervision of the Ministry of Health and Medical Education. The study was approved by the TUMS ethics committee and received a Clinical Trial Authorization- CTA from the Food and Drug Administration before the study began.

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Tehran University of Medical Sciences

Street address

Room 105 , 5th floor, Central construction of Tehran University of Medical Sciences, Ghods intersection, Keshavarz blvd.

City

Tehran

Province

Tehran

Postal code

1417653761

Approval date

2020-03-17, 1398/12/27

Ethics committee reference number

IR.TUMS.VCR.REC.1398.1076

Health conditions studied

1

Description of health condition studied

COVID-19

ICD-10 code

U07.1

ICD-10 code description

Clinically-epidemiologically diagnosed COVID-19, Probable COVID-19, Suspected COVID-19

Primary outcomes

1

Description

Time to Clinical Improvement (TTCI): TTCI is defined as the time (in days) from initiation of study treatment until a decline of two categories from admission status on a six-category ordinal scale of clinical status which ranges from 1 (discharged) to 6 (death).6. Death; 5. ICU, requiring ECMO and/or IMV; 4. ICU/hospitalization, requiring NIV/ HFNC therapy;3. Hospitalization, requiring supplemental oxygen (but not NIV/ HFNC);2. Hospitalization, not requiring supplemental oxygen; 1.

Hospital discharge. IMV, invasive mechanical ventilation; NIV, non-invasive mechanical ventilation; HFNC, High-flow nasal cannula.

Timepoint

Daily for 14 days

Method of measurement

Based on clinical evaluation

2**Description**

Time to Clinical recovery (TTCR): TTCR is defined as the time (in hours) from initiation of study treatment until normalization of fever, respiratory rate, and oxygen saturation, and alleviation of cough sustained for at least 72 hours. Normalization and alleviation criteria: • Fever - $\leq 36.9^{\circ}\text{C}$ or -axilla, $\leq 37.2^{\circ}\text{C}$ oral, • Respiratory rate - $\leq 24/\text{minute}$ on room air, • Oxygen saturation - $>94\%$ on room air, • Cough - mild or absent on a patient-reported scale of severe, moderate, mild, absent.

Timepoint

Daily for 14 days

Method of measurement

Based on clinical evaluation

Secondary outcomes**1****Description**

Percentage of patients with improved oxygen supply: Percentage of patients with improved oxygen supply (at least one step in reducing oxygen supply) including 1-no need for additional oxygen supply. 2. Nasal oxygen catheter inhalation 3. Oxygen inhalation with mask. 4- NIV 5- Ventilator

Timepoint

Daily for 14 days

Method of measurement

Based on clinical evaluation

2**Description**

PaO₂ / FiO₂ ratio: lowest fraction recorded in a day

Timepoint

Daily for 14 days

Method of measurement

Oximeter

3**Description**

The extent of lung involvement in CT scan

Timepoint

At baseline and 14th day

Method of measurement

Radiologist report basis

4**Description**

Any adverse event

Timepoint

During the study period

Method of measurement

Any events during the study according to the patient's report or physician's judgment

5**Description**

All cause mortality

Timepoint

During the 28 days after starting the intervention

Method of measurement

Hospital death record or statement by relatives after discharge

Intervention groups**1****Description**

Intervention group: In addition to standard treatment: (two-drug regimen including 500 mg chloroquine phosphate / 400 mg hydroxychloroquine sulfate; single-dose and lopinavir/ritonavir 400/100 mg BID for at least 5 days or alternatively, atazanavir OR three-drug regimen including 500 mg chloroquine phosphate / 400 mg hydroxychloroquine sulfate; single-dose and lopinavir/ritonavir 400/100 mg BID for at least 5 days and ribavirin 1200 mg BID for at least 5 days) Remdesivir is also prescribed for 5 days (for patients over 40 kg or more: Amp Remdesivir 200 mg IV infusion over 30 minutes once-daily dose, followed by 100 mg iv infusion over 30 minutes once-daily maintenance doses for next 4 days. For patients weighing less than 40 kg: Amp Remdesivir 5 mg/kg IV infusion over 30 minutes loading dose on day 1, followed by 2.5 mg/kg iv infusion over 30 minutes once-daily maintenance doses for next 4 days)

Category

Treatment - Drugs

Recruitment centers**1****Recruitment center****Name of recruitment center**

Imam Khomeini Hospital

Full name of responsible person

Mohammad Reza Salehi

Street address

Imam Khomeini Hospital, Keshavarz Blvd at Gharib St., Tehran, Iran

City

Tehran

Province

Tehran

Postal code

1419733141

Phone

+98 21 8896 3546

Email

ctc@tums.ac.ir

Web page address

<http://ikhc.tums.ac.ir/>

2**Recruitment center****Name of recruitment center**

Masih Daneshvari

Full name of responsible person

Payam Tabarsi

Street address

Daar Abad, Niavaran, Masih Daneshvarai Hospital

City

Tehran

Province

Tehran

Postal code

1956944413

Phone

+98 21 2610 6000

Fax

+98 21 2610 9680

Email

pr.nritld@sbmu.ac.ir

Web page address

<https://nritld.sbmu.ac.ir/index.jsp?fkeyid=&siteid=200&pageid=1419>

3**Recruitment center****Name of recruitment center**

Sina Hospital

Full name of responsible person

Azar Haddadi

Street address

Sina Hospital, Hasan Abad Square, Tehran, Iran

City

Tehran

Province

Tehran

Postal code

1136746911

Phone

+98 21 6634 8500

Fax

+98 21 6634 8553

Email

Hadadiaz@tums.ac.ir

Web page address

<http://sinahospital.tums.ac.ir/>

4**Recruitment center****Name of recruitment center**

Baqiyatallah Hospital

Full name of responsible person

Mostafa Ghanei

Street address

Baqiyatallah Hospital, Mulla Sadra Street, Vanak

Square, Tehran, Iran.,

City

Tehran

Province

Tehran

Postal code

1435915371

Phone

+98 21 8805 0436

Fax

+98 21 8805 0436

Email

m.ghanei@bmsu.ac.ir

Web page address

<https://baq.bmsu.ac.ir/Portal/home/?283090/english>

5**Recruitment center****Name of recruitment center**

Rasool Akram Hospital

Full name of responsible person

Saeed Kalantari

Street address

Hazrate Rasoole Akram Hospital, Niayesh St, Satarkhan Av, Tehran, IRAN

City

Tehran

Province

Tehran

Postal code

1449614535

Phone

+98 21 6435 2564

Fax

+98 21 6650 2248

Email

kalantari.s@iums.ac.ir

Web page address

<https://hrmc.iums.ac.ir/>

6**Recruitment center****Name of recruitment center**

Loghman Hospital

Full name of responsible person

Ilad Alavi Darazam

Street address

Makhsoos St, South Karegar Ave, Tehran, Iran

City

Tehran

Province

Tehran

Postal code

1333635445

Phone

+98 21 5541 9005

Fax

+98 21 5541 7547

Email

Ilad13@yahoo.com

Web page address

<http://lhmc.sbmuc.ac.ir/>

7

Recruitment center

Name of recruitment center

AmirAlam Hospital

Full name of responsible person

Mehrdad Hasibi

Street address

Saadi St., Enghelab St., Tehran, Iran.

City

Tehran

Province

Tehran

Postal code

1145765111

Phone

+98 21 6672 7060

Fax

+98 21 6670 4805

Email

mehrdad_hasibi@yahoo.com

Web page address

<http://amiralam.tums.ac.ir/>

8

Recruitment center

Name of recruitment center

Al-Zahra Hospital

Full name of responsible person

Farzin Khorvash

Street address

Al-Zahra Hospital, Soffeh Blvd, Isfahan

City

Isfahan

Province

Isfahan

Postal code

8174675731

Phone

+98 31 3620 2020

Fax

+98 31 3669 1510

Email

Farzin300@gmail.com

Web page address

<http://alzahra.mui.ac.ir/>

9

Recruitment center

Name of recruitment center

Imam Reza Hospital

Full name of responsible person

Rozita Khodashahi

Street address

Imam Reza Hospital, Imam Reza square, Ibne Sina Street, Mashhad, Iran

City

Mashhad

Province

Razavi Khorasan

Postal code

9137913316

Phone

+98 51 3858 3845

Fax

+98 51 3858 3845

Email

khodashahir@mums.ac.ir

Web page address

<https://emamreza.mums.ac.ir/>

10

Recruitment center

Name of recruitment center

Razi Hospital

Full name of responsible person

Aydin PoorKazemi

Street address

Razi Hospital, Sardar St., Rasht, Iran.

City

Rasht

Province

Guilan

Postal code

41448

Phone

+98 13 3355 0028

Fax

+98 13 3355 9787

Email

razi.hospital@yahoo.com

Web page address

<http://www.gums.ac.ir/razi/default.aspx?tabid=444>

11

Recruitment center

Name of recruitment center

Razi Hospital

Full name of responsible person

Farhang BabaMahmoudi

Street address

Razi Hospital, Yusef Reza St., GhaemShahr, Iran.

City

Ghaemshahr

Province

Mazandaran

Postal code

4765686743

Phone

+98 11 4221 8018

Fax

+98 11 4221 8011

Email

Farhang.baba@yahoo.com

Web page address

<https://razihospital.mazums.ac.ir/>

12

Recruitment center

Name of recruitment center

Beheshti Hospital

Full name of responsible person

Mansoorreh Momen-Heravi

Street address

Ravandi Blvd, Beheshti Hospital, Kashan, Iran

City

Kashan

Province

Isfahan

Postal code

8715981151

Phone

+98 31 5554 0026

Fax

+98 31 5554 8900

Email

mansoreheravi@yahoo.com

Sponsors / Funding sources**1****Sponsor****Name of organization / entity**

Tehran University of Medical Sciences

Full name of responsible person

Reza Malekzadeh

Street address

Digestive Disease Research Institute, Shariati Hospital, Kargar Street, Tehran

City

Tehran

Province

Tehran

Postal code

1411713135

Phone

+98 21 8241 5000

Fax

+98 21 8241 5400

Email

info@ddri.ir

Web page address

https://ddri.ir/

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

Title of funding source

Tehran University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin**Type of organization providing the funding**

Academic

Person responsible for general inquiries**Contact****Name of organization / entity**

Tehran University of Medical Sciences

Full name of responsible person

Hamed Hosseini

Position

Assistant professor in Epidemiology

Latest degree

Ph.D.

Other areas of specialty/work

Epidemiology

Street address

23rd Unit, 4th Floor, No. 1547, North Kargar St.,

City

Tehran

Province

Tehran

Postal code

1417993337

Phone

+98 21 8896 3546

Fax

+98 21 8896 3546

Email

ctc@tums.ac.ir

Web page address

http://ctc.tums.ac.ir

Person responsible for scientific inquiries**Contact****Name of organization / entity**

Tehran University of Medical Sciences

Full name of responsible person

Mohammad Reza Salehi

Position

Assistant Professor of Infectious Disease

Latest degree

Specialist

Other areas of specialty/work

Infectious diseases

Street address

Imam Khomeini Hospital Complex, Gharib | Keshavarz intersection, Tehran, Iran.

City

Tehran

Province

Tehran

Postal code

1419733141

Phone

0098 21 61190

Email

imamhospital@tums.ac.ir

Web page address

http://ikhc.tums.ac.ir/

Person responsible for updating data

Contact

Name of organization / entity

Tehran University of Medical Sciences

Full name of responsible person

Hamed Hosseini

Position

Associate professor in Epidemiology

Latest degree

Ph.D.

Other areas of specialty/work

Epidemiology

Street address

23 th unit, 4th floor, No 1547, North Kargar Street,

City

Tehran

Province

Tehran

Postal code

1417993337

Phone

+98 21 8896 3546

Fax

+98 21 8896 3546

Email

hmdhosseini@gmail.com

Web page address

<http://ctc.tums.ac.ir>

Sharing plan

Deidentified Individual Participant Data Set (IPD)

No - There is not a plan to make this available

Justification/reason for indecision/not sharing IPD

The DSMB decides how the results will be disseminated after reviewing the preliminary data.

Study Protocol

No - There is not a plan to make this available

Statistical Analysis Plan

No - There is not a plan to make this available

Informed Consent Form

No - There is not a plan to make this available

Clinical Study Report

No - There is not a plan to make this available

Analytic Code

No - There is not a plan to make this available

Data Dictionary

No - There is not a plan to make this available